CSIMarket Company Name, Ticker, Competitors, else..
 
Achieve Life Sciences Inc   (NASDAQ: ACHV)
Other Ticker:  
 
 
Price: $2.1600 $-0.01 -0.461%
Day's High: $2.2292 Week Perf: 0.93 %
Day's Low: $ 2.11 30 Day Perf: -25.77 %
Volume (M): 111 52 Wk High: $ 5.59
Volume (M$): $ 240 52 Wk Avg: $4.16
Open: $2.17 52 Wk Low: $1.84



 Market Capitalization (Millions $) 69
 Shares Outstanding (Millions) 32
 Employees 25
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -40
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Achieve Life Sciences Inc
Achieve Life Sciences Inc is a pharmaceutical company focused on developing and commercializing treatments for nicotine addiction. The company's lead product candidate is cytisine, a plant-based alkaloid that has been used for smoking cessation in Eastern Europe for several decades. Achieve Life Sciences aims to leverage the established efficacy and safety profile of cytisine to provide an effective and affordable treatment option for smokers looking to quit. The company is actively conducting clinical trials to evaluate the potential of cytisine as a smoking cessation therapy.


   Company Address: 1040 West Georgia Street Vancouver 0 BC
   Company Phone Number: 210-2217   Stock Exchange / Ticker: NASDAQ ACHV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CARA        8.57% 
INDV   -5.99%    
• View Complete Report
   



Management Changes

Achieve Life Sciences Strengthens Leadership and Progresses Toward Smoking Cessation Breakthrough with Cytisinicline

Published Wed, Oct 16 2024 12:00 PM UTC

In a dynamic move poised to bolster its commercial strategy, Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company renowned for its innovative approach to nicotine dependence treatment, has announced the promotion of Ms. Jaime Xinos to the role of Chief Commercial Officer, effective immediately. This strategic decision comes against the backdrop of ...
Clinical Study

Achieve Life Sciences Completes Enrollment in ORCA-OL Trial Amid Successful Monitoring Review A Positive Step Forward

Published Thu, Oct 10 2024 12:00 PM UTC

In a significant advancement for tobacco harm reduction strategies, Achieve Life Sciences Inc. recently announced the completion of enrollment in its ORCA-OL clinical trial, a pivotal study exploring the efficacy of its lead therapeutic, cytisine, for smoking cessation. This milestone comes at a time when public health officials are increasingly focused on novel intervention...
Clinical Study

Cytisinicline A Promising New Hope for E-Cigarette Dependence Amidst Growing Public Health Concerns

Published Wed, Jul 31 2024 12:01 PM UTC

As public health officials continue to grapple with the rising tide of nicotine dependence linked to electronic cigarettes and vaping, emerging therapies are vital in addressing this growing epidemic. In this context, Achieve Life Sciences has recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to cytisinicline fo...
Financing Agreement

Securing Success: Achieve Life Sciences Extends Loan With Silicon Valley Bank, Paving the Way for Innovation

Published Mon, Jul 29 2024 12:00 PM UTC

Achieve Life Sciences Secures $20M Loan Refinancing with Silicon Valley Bank, Extending Maturity Date to 2027
Achieve Life Sciences, a prominent late-stage pharmaceutical company specializing in smoking cessation and nicotine dependence, has recently announced a significant milestone in its financial operations. The company has entered into a $20 million debt refinancing...
Management Announcement

Achieve Life Sciences Finds Recognition in U.S. Russell Indexes, Signaling Potential Growth in Smoking Cessation Market

Published Mon, Jul 1 2024 12:00 PM UTC



Seattle and Vancouver, British Columbia - Achieve Life Sciences, Inc. (Nasdaq: ACHV), a renowned late-stage pharmaceutical firm dedicated to the worldwide development and commercialization of cytisinicline for smoking cessation and nicotine dependence, proudly announced its recent inclusion in the esteemed U.S. Russell 3000 and Russell Microcap Indexes. Effective i...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com